ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Jonathan W. Riess(University of California Davis Medical Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Sarah B. Goldberg(Yale University), Kwan Ho Tang(AstraZeneca (Netherlands)), Jonathan W. Goldman(University of California, Los Angeles), Adrianus J. de Langen(The Netherlands Cancer Institute), Byoung Chul Cho(Yonsei University), Riccardo Cavazzina, Zofia Piotrowska(Global Cancer Institute), Santiago Ponce(Spanish National Cancer Research Centre), James Y. Lau(Chinese University of Hong Kong), Yasuto Yoneshima(Kyushu University), Helen Ambrose(AstraZeneca (United Kingdom)), Xiuning Le(The University of Texas MD Anderson Cancer Center)
JCO Precision Oncology
June 1, 2025
10.1200/po-24-00818
Cited by 10

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k